Loomis, Sayles & Company’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Loomis, Sayles & Company’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-75	Closed	-$4K	–	1203
2016 Q1	$4K	Sell	75 -116,301	-100%	-$8.59M	﹤0.01%	973
2015 Q4	$13.1M	Buy	116,376 +29,006	+33%	+$3.2M	0.04%	378
2015 Q3	$10.3M	Sell	87,370 -90,207	-51%	-$11.8M	0.03%	424
2015 Q2	$13.8M	Sell	177,577 -107,359	-38%	-$7.04M	0.04%	423
2015 Q1	$16.5M	Sell	284,936 -191,862	-40%	-$8.15M	0.05%	391
2014 Q4	$15.4M	Sell	476,798 -329,824	-41%	-$9.9M	0.04%	419
2014 Q3	$19.7M	Buy	+806,622	New	+$16.4M	0.06%	319

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Loomis, Sayles & Company's ANAC Position: Q2 2016 in Review

Loomis, Sayles & Company sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 75 shares — an estimated $4K sold.

Loomis, Sayles & Company first reported a position in ANAC in Q3 2014 and held it in 7 quarters. The position peaked at $19.7M in Q3 2014. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

Loomis, Sayles & Company reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
Loomis, Sayles & Company sold 75 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $4K.
Loomis, Sayles & Company first reported a position in ANACOR PHARMACEUTICALS INC COM in Q3 2014 and held it in 7 quarters.
Loomis, Sayles & Company's ANACOR PHARMACEUTICALS INC COM position peaked at $19.7M in Q3 2014.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Loomis, Sayles & Company's 13F filing for Q2 2016, filed 12 Aug 2016.